Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review | Neurology and Therapy
Defining a role for laquinimod in multiple sclerosis - Bernd C. Kieseier, 2014
Laquinimod - Wikipedia
Teva scales back R&D as Copaxone competition looms - PMLiVE
Meet the Compound: Laquinimod – HD Insights
Molecules | Free Full-Text | Laquinimod Modulates Human Astrocyte Function and Dampens Astrocyte-Induced Neurotoxicity during Inflammation
With Continuous Failure Active Biotech Regains Global Rights for Laquinimod from Teva
Teva Pharmaceuticals - Wikiwand
Laquinimod - Wikipedia
Active Bio and Teva's laquinimod strikes out again, this time in progressive MS | Fierce Biotech
A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis | Neurology
Form 10-K
Laquinimod attenuates inflammation by modulating macrophage functions in traumatic brain injury mouse model | Journal of Neuroinflammation | Full Text
Laquinimod dampens IL-1β signaling and Th17-polarizing capacity of monocytes in patients with MS | Neurology Neuroimmunology & Neuroinflammation
After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
425
425
Laquinimod - an overview | ScienceDirect Topics
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis - Giancarlo Comi, Yuval Dadon, Nissim Sasson, Joshua R Steinerman, Volker Knappertz, Timothy L Vollmer, Alexey Boyko, Patrick Vermersch, Tjalf
Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS | Journal of Neuroinflammation | Full Text
Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells - Dobson - 2016 - Journal of Neurochemistry - Wiley Online Library
Laquinimod dampens IL-1β signaling and Th17-polarizing capacity of monocytes in patients with MS | Neurology Neuroimmunology & Neuroinflammation
